- Home
- HEQ vs ACRS Comparison
HEQ vs ACRS Comparison
Compare HEQ & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEQ
- ACRS
- Stock Information
- Founded
- HEQ 2011
- ACRS 2012
- Country
- HEQ United States
- ACRS United States
- Employees
- HEQ N/A
- ACRS N/A
- Industry
- HEQ Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- HEQ Finance
- ACRS Health Care
- Exchange
- HEQ Nasdaq
- ACRS Nasdaq
- Market Cap
- HEQ 126.1M
- ACRS 132.0M
- IPO Year
- HEQ N/A
- ACRS 2015
- Fundamental
- Price
- HEQ $10.49
- ACRS $2.57
- Analyst Decision
- HEQ
- ACRS Strong Buy
- Analyst Count
- HEQ 0
- ACRS 5
- Target Price
- HEQ N/A
- ACRS $11.00
- AVG Volume (30 Days)
- HEQ 43.1K
- ACRS 1.0M
- Earning Date
- HEQ 01-01-0001
- ACRS 02-25-2025
- Dividend Yield
- HEQ 9.78%
- ACRS N/A
- EPS Growth
- HEQ N/A
- ACRS N/A
- EPS
- HEQ N/A
- ACRS N/A
- Revenue
- HEQ N/A
- ACRS $27,079,000.00
- Revenue This Year
- HEQ N/A
- ACRS N/A
- Revenue Next Year
- HEQ N/A
- ACRS N/A
- P/E Ratio
- HEQ N/A
- ACRS N/A
- Revenue Growth
- HEQ N/A
- ACRS 26.35
- 52 Week Low
- HEQ $9.08
- ACRS $0.95
- 52 Week High
- HEQ $11.84
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- HEQ 53.21
- ACRS 43.12
- Support Level
- HEQ $10.15
- ACRS $2.31
- Resistance Level
- HEQ $10.39
- ACRS $2.57
- Average True Range (ATR)
- HEQ 0.11
- ACRS 0.18
- MACD
- HEQ 0.04
- ACRS 0.00
- Stochastic Oscillator
- HEQ 94.44
- ACRS 39.45
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.